CN1823875A - Medicinal composition of trichosanthes rind and its preparation method - Google Patents
Medicinal composition of trichosanthes rind and its preparation method Download PDFInfo
- Publication number
- CN1823875A CN1823875A CN 200510121133 CN200510121133A CN1823875A CN 1823875 A CN1823875 A CN 1823875A CN 200510121133 CN200510121133 CN 200510121133 CN 200510121133 A CN200510121133 A CN 200510121133A CN 1823875 A CN1823875 A CN 1823875A
- Authority
- CN
- China
- Prior art keywords
- pericarpium trichosanthis
- injection
- extract
- pericarpium
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A freeze-dried powder injection for treating cardiovascular and cerebrovascular diseases is prepared from the extract of trichosanthes bark (5-100 Wt%) and the harmacologically acceptable auxiliary (0-5 Wt%). Its preparing process is also disclosed.
Description
Technical field:
The present invention relates to a kind of pharmaceutical composition of Pericarpium Trichosanthis, particularly a kind of snakegourd peel lyophilized powder injection agent composition and method of making the same.
Background technology:
Pericarpium Trichosanthis is the dry mature skin of cucurbitaceous plant Fructus Trichosanthis Trichosanthes kirilowii Maxim. or trichosanthes rosthornii Harms Trichos-anthes rosthornii Harms.Pluck mature fruit autumn, cut open, remove fruit flesh and seed, dry in the shade promptly, voluminous in the Hunan, ground such as Hubei, Guizhou, Sichuan.Fructus Trichosanthis contains triterpene saponin, organic acid, resin, saccharide, pigment etc., and seed contains fatty oil.Traditional medicine is thought sweet, the little hardship of Pericarpium Trichosanthis, and is cold, goes into lung, stomach and large intestine channel.Have relieving stuffiness of the chest by dispersing aggregation of pathogens, lung moistening is eliminated the phlegm, the effect of laxation relieving constipation.Tradition is used for phlegm-heat cough, the vexed pain in ambition, and mammitis, the liquid dry stool is secret.
Modern study shows that Pericarpium Trichosanthis contains each seed amino acid and volatile ingredient more, and clinical development has the application of Pericarpium Trichosanthis injection.Pericarpium Trichosanthis injection has coronary artery dilator, blood flow increasing, improves the microcirculatory effect of myocardial ischemia, and the acute myocardial ischemia that particularly resists due to the pituitrin has significant protective effect.The clinical literature report, 120 routine angina pectoris patients, the treatment group is used Pericarpium Trichosanthis injection therapeutic dose 10ml, adds quiet of 0.9% normal saline or 5% glucose injection 150ml, and 15d is 1 course of treatment.The oral isosorbide mononitrate of matched group 20mg/ time, 3 times/day, 15d is 1 course of treatment; Or add isoptin 5mg/ time, 2 times/day, 15d is 1 course of treatment.The result shows: on symptom, treatment group and matched group curative effect are through statistical procedures, and difference has significance (P＜0.05), illustrate that Pericarpium Trichosanthis injection treatment angina pectoris effect is better than isosorbide mononitrate and isoptin.Clinical effectiveness shows that treatment group total effective rate up to 95%, obviously is better than matched group.
The Pericarpium Trichosanthis injection clinical practice for many years, curative effect has obtained conclusive evidence.But the technology and the cognitive level that are limited at that time inevitably exist some defectives, mainly show 1) dosage form of injection be because will exist the problem of effective ingredient high temperature loss through the technology of sterilization; 2) injection is not easy to preserve, transportation, some specific conditions can not use (for example utmost point low temperature environment); 3) less stable is placed with for a long time and may produces muddiness.These are all having a strong impact on the clinical practice of Pericarpium Trichosanthis, even produce clinical adverse.We creatively are applied to the dosage form of novel lyophilized powder in the Pericarpium Trichosanthis ejection preparation, it is generally acknowledged that those of ordinary skill can not predict that Pericarpium Trichosanthis changes the problem that the injection lyophilized powder is run into into, and the preparation technology that we attempt conclusive evidence injection Pericarpium Trichosanthis lyophilized powder by a large amount of experiment, this neither those of ordinary skill just can not solve by performing creative labour.
Summary of the invention:
One of purpose of the present invention is the deficiency that overcomes existing Pericarpium Trichosanthis injection, and a kind of snakegourd peel lyophilized powder injection agent is provided, and another object of the present invention provides the preparation method of this injection Pericarpium Trichosanthis lyophilized powder.
In order to reach above-mentioned technical purpose, we have taked following technological means:
We provide a kind of pharmaceutical composition of Pericarpium Trichosanthis, are freeze-dried powder injections, and by the extract 5-100% weight portion of Pericarpium Trichosanthis, pharmaceutically acceptable pharmaceutic adjuvant 0-95% weight portion is formed.
Preferably by the extract 5-20% weight portion of Pericarpium Trichosanthis, pharmaceutically acceptable pharmaceutic adjuvant 80-95% weight portion is formed.
The content of total amino acids is counted more than 25% with arginine in the wherein said Pericarpium Trichosanthis extract.The content of total amino acids is not less than 80% in arginine in the preferred Pericarpium Trichosanthis extract.
Every loading amount Pericarpium Trichosanthis extract of injection Pericarpium Trichosanthis lyophilized powder that we provide is no less than 35mg.
Pericarpium Trichosanthis pharmaceutical composition of the present invention, wherein Pericarpium Trichosanthis extract can be following method preparation: get the recipe quantity Pericarpium Trichosanthis and decoct with water three times, 2 hours for the first time, second, three times each 1 hour, gradation filtered, and merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), adding ethanol makes and contains the alcohol amount and reach 70%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol, by 732 type cation exchange resiies, with an amount of washing resin of water for injection, reuse 1mol/L ammonia solution eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract;
Wherein acceptable accessories comprises the skeleton proppant that lyophilizing is used, and can be in mannitol, lactose, mannose, sorbitol, the low molecular dextran one or more.
Preferred skeleton proppant uses mannitol, and the concentration of mannitol is 4-12% before the lyophilizing.Concentration before the preferred mannitol lyophilizing is 8%.
In order to add solubilizing agent and the antioxidant of pharmaceutically accepting in the stability composition that increases medicine.
We provide the preparation method of injection Pericarpium Trichosanthis lyophilized powder, may further comprise the steps:
1) gets the recipe quantity Pericarpium Trichosanthis and decoct with water three times, merge three extracting solution and be evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), add high concentration ethanol and make and contain the alcohol amount and reach 60-80%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol to there not being the alcohol flavor, by cation exchange resin, with an amount of washing resin of water for injection, reuse ammonia spirit eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract;
2) Pericarpium Trichosanthis extract fully is dissolved in the water for injection, regulates pH value to 3-4 with hydrochloric acid, cold preservation 24 hours filters, and filtrate adds injection supplementary material, regulates pH value to 6.0-7.5 with sodium hydroxide test solution, fine straining, and packing, lyophilizing are promptly.
We provide injection Pericarpium Trichosanthis lyophilized powder to obtain by following method:
1) getting the recipe quantity Pericarpium Trichosanthis decocts with water three times, 2 hours for the first time, second and third time each 1 hour, gradation filters, merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), adds 90% ethanol and makes and contain alcohol amount and reach 70%, leaves standstill 24 hours, get supernatant, filter, reclaim ethanol, by 732 type cation exchange resiies, with an amount of washing resin of water for injection, reuse 1mol/L ammonia solution eluting is collected eluent, and decompression removes the deammoniation flavor, and be concentrated into thick paste final vacuum drying, get Pericarpium Trichosanthis extract.
2) Pericarpium Trichosanthis extract of getting step 1) fully is dissolved in the water for injection, regulates pH value to 3-4 with hydrochloric acid, and cold preservation 24 hours filters, and filtrate is regulated pH value to 7.0 with sodium hydroxide test solution, fine straining after the active carbon decarburization, and packing, lyophilizing are promptly.
In order to obtain the step that the stable better method above the preparation can also comprise ultrafiltration, being meant step 2) middle cold preservation is after 24 hours, and subsequent filtrate is crossed 5000 ultrafilter membrane ultrafiltration, ultrafiltrate reuse sodium hydroxide test solution is regulated pH value to 6.0-7.5, fine straining, packing, lyophilizing gets final product.
We find to regulate before the lyophilizing pH value to 7.0 in the experiment, are dissolved with good help again for lyophilized powder.
The present invention also provides the application in the medicine aspect preparation treatment cardiovascular and cerebrovascular disease of described Pericarpium Trichosanthis pharmaceutical composition.Wherein Pericarpium Trichosanthis extract using dosage every day is 150mg to 400mg.Preferred Pericarpium Trichosanthis extract using dosage every day is 200mg.
Preparation by our success of a large amount of experiments the injectable powder of injection Pericarpium Trichosanthis, and provide the preparation method of injection Pericarpium Trichosanthis lyophilized powder.This method process stabilizing, favorable reproducibility have reached preferred purpose, preferably increase ultrafiltration step preparation stability is significantly improved, and reduced solid content on the basis that guarantees effective ingredient, have reduced color.The dosage form of lyophilized powder has successfully solved the problem that former Pericarpium Trichosanthis injection exists; pharmacological evaluation proves that the injection Pericarpium Trichosanthis lyophilized powder that we prepare has the curative effect of good treatment cardiovascular and cerebrovascular disease, especially shows good effect to the anoxia enduring of mice and the protection of ischemical reperfusion injury.
Specific embodiment:
Embodiment 1: the preparation of injection Pericarpium Trichosanthis lyophilized powder
Getting the 5kg Pericarpium Trichosanthis decocts with water three times, each 10 times of amounts, 2 hours for the first time, second, three times each 1 hour, gradation filtered, and merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃) (measured value 1.20), adding 95% medicinal alcohol makes and contains alcohol amount and reach 70%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol, by 732 good type cation exchange resiies of pretreatment, with an amount of washing resin of water for injection, reuse 1mol/L ammonia spirit eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract.
Pericarpium Trichosanthis extract fully is dissolved in the 500ml water for injection, regulate pH value to 3-4 with hydrochloric acid, cold preservation 24 hours filters, and filtrate adds mannitol 60g, fully the dissolving back replenishes water for injection to 1000ml, regulate pH value to 7.0 with sodium hydroxide test solution, fine straining after the active carbon decarburization divides to be filled in the 7ml cillin bottle, every 4ml, lyophilizing promptly.
Embodiment 2: the preparation of injection Pericarpium Trichosanthis lyophilized powder
With reference to the method for embodiment 1, writing out a prescription is:
Pericarpium Trichosanthis: 5000g
Mannitol: 40g
Make 1000ml, loading amount 4ml.
Embodiment 3: the preparation of injection Pericarpium Trichosanthis lyophilized powder
With reference to the method for embodiment 1, writing out a prescription is:
Pericarpium Trichosanthis: 5000g
Mannitol: 80g
Sodium sulfite: 1g
Make 1000ml, loading amount 4ml.
Embodiment 4: the preparation of injection Pericarpium Trichosanthis lyophilized powder
With reference to the method for embodiment 1, writing out a prescription is:
Pericarpium Trichosanthis: 5000g
Mannitol: 100g
Husky nurse: the 5g of POLO
Make 1000ml, loading amount 4ml.
Embodiment 5: the preparation of injection Pericarpium Trichosanthis lyophilized powder
The method of reference example 1, writing out a prescription is:
Pericarpium Trichosanthis: 5000g
Dextran: 100g
Make 1000ml, loading amount 4ml.
Embodiment 6: the preparation of injection Pericarpium Trichosanthis lyophilized powder
Getting the 5kg Pericarpium Trichosanthis decocts with water three times, each 10 times of amounts, 2 hours for the first time, second, three times each 1 hour, gradation filtered, and merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃) (measured value 1.20), adding 95% medicinal alcohol makes and contains alcohol amount and reach 70%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol, by 732 good type cation exchange resiies of pretreatment, with an amount of washing resin of water for injection, reuse 1mol/L ammonia spirit eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract.
Pericarpium Trichosanthis extract fully is dissolved in the 500ml water for injection, regulate pH value to 3-4 with hydrochloric acid, cold preservation 24 hours filters, subsequent filtrate is crossed 5000 ultrafilter membrane ultrafiltration, ultrafiltrate adds mannitol 60g, and fully the dissolving back replenishes water for injection to 1000ml, regulates pH value to 7.0 with sodium hydroxide test solution, fine straining after the active carbon decarburization, divide to be filled in the 7ml cillin bottle, every 3ml, lyophilizing is promptly.
Embodiment 7: the protective effect research experiment medicine that injection Pericarpium Trichosanthis lyophilized powder damages rat myocardial ischemia and reperfusion: injection Pericarpium Trichosanthis lyophilized powder of the present invention (section's medicament research and development company limited provides in the Guangdong).Add in the experiment water for injection by required dissolving prepare Pericarpium Trichosanthis injection.
Radix Salviae Miltiorrhizae Injection
Normal saline
Laboratory animal: 50 of Wistar II level rat, male and female half and half, body weight 200g-250g
Experimental technique:
With coronary ligation manufactured rat myocardial ischemia and reperfusion damage model, rats by intraperitoneal injection 3% pentobarbital sodium anesthesia (30mg/kg), place on the rat operating-table fixedly dorsal position to fix, the longitudinal incision skin of neck, passivity is separated the trachea surrounding tissue, exposes trachea, circulation of qi promoting pipe interpolation pipe, and confirm to insert in the trachea, back suture fixedly intubate by the rat mouth.In rat oxter parallel lines, transection skin about 1.5cm in left side separates the flesh layer in the 4th or the 5th intercostal passivity, opens the thoracic cavity, is right after animal respirator, auxiliary rats breathing.Cut off pericardium, gently press the right side thorax, extrude heart, at pulmonary conus right border, flat left auricle lower edge 1-2mm place, superficial layer of myocardium is worn line No. 5/0 under left coronary artery, together with a diameter 2mm polrvinyl chloride tubal ligation left anterior descending coronary artery, causes myocardial ischemia.Behind the ligation arteria coronaria 1 hour, cut off polychlorostyrene second pipe with eye scissors and cut off silk thread simultaneously, make ischemic myocardium recover blood perfusion, pour into again and finish experiment after 3 hours.Lead the sign that the model success was raised or be reduced to the ST section with SUMP-PC type four roads biological signal acquisition process continuous record standard limbs II in the whole experiment.
The experiment grouping:
At random 50 rats are divided into 5 groups, 10 every group.1. sham operated rats: only cut the thoracic cavity, expose heart, threading but not ligation coronary artery, lumbar injection isotonic saline solution 2ml.2. model group: threading ligation coronary artery immediately behind the lumbar injection isotonic saline solution 2ml, is made into ischemia 1h, pours into the 3h rat model again.3. low dose group: threading ligation coronary artery, lumbar injection Fructus Trichosanthis injection (behind the 1g crude drug/kg), is made into ischemia 1h, pours into the 3h rat model more immediately.4. high dose group: threading ligation coronary artery, the Pericarpium Trichosanthis injection of lumbar injection preparation immediately (behind the 3g crude drug/kg), is made into ischemia 1h, pours into the 3h rat model again.5. Radix Salviae Miltiorrhizae Injection matched group: threading ligation coronary artery, the lumbar injection Radix Salviae Miltiorrhizae Injection (behind the 0.2g crude drug/kg), is made into ischemia 1h, pours into the 3h rat model more immediately.
Detect index:
(1) rat blood serum CPK, LDH, SOD, the MDA determination of activity, at once treating the preponderant disease instead of the secondary disease blood 5ml separation of serum after perfusion finishes again, creatine phosphokinase (CPK) and lactic acid dehydrogenase (LDH) press test kit mensuration enzymatic activity, SOD are described, malonaldehyde (MDA) detects activity of SOD in serum and MDA content according to the test kit operation with UV-754 type ultraviolet-uisible spectrophotometer.The results are shown in Table 1.
(2) detection of NO, NOS, SOD, MDA content in the cardiac muscular tissue, after perfusion finishes again the rat of modeling success is put to death, the dirty tissue of coring rapidly, with the clean cardiac muscular tissue of ice normal saline flushing bloodstain, after making 10% myocardium homogenate under 4 ℃ of conditions, the centrifugal 10min of 4000r/min gets supernatant.Myocardium NO, NOS, SOD activity and MDA content are measured in explanation according to test kit.The results are shown in Table 2.
Table 1 injection Pericarpium Trichosanthis lyophilized powder is to CPK in the rat myocardial ischemia and reperfusion damage serum, LDH, SOD, the influence of MDA
| Group | Example number (n) | CPK (U/L) | LDH (U/L) | SOD (U/L) | MDA (umol/L) |
| Sham operated rats model group low dose group high dose group Radix Salviae Miltiorrhizae group | 10 10 10 10 10 | 135.6±7.2 1215.8±125.3 595.5±28.9 △△ 359.1±23.5 △△ 442.9±31.2 △△ | 39.6±1.3 321.5±24.6 119.4±14.2 △△ 86.7±9.2 △△ 98.6±13.4 △△ | 408±31 329±22 372±24 △△ 397±35 △△ 387±24 △△ | 4.2±1.2 11.5±2.6 6.5±1.3 △△ 5.1±1.4 △△ 4.5±2.3 △△ |
Annotate: compare △ P＜0.05 △ △ P＜0.01 with model group
Table 2 injection Pericarpium Trichosanthis lyophilized powder is organized NO to the rat myocardial ischemia and reperfusion injury of myocardium, NOS, SOD, the influence of MDA
| Group (nmol/mg) | The example number | NO (nmol/mg) | NOS (nmol/100mg) | MDA (NU/100mg) | SOD |
| Sham operated rats model group low dose group high dose group Radix Salviae Miltiorrhizae group | 10 10 10 10 10 | 4.69±0.25 2.25±0.14 3.78±0.16 △△ 4.41±0.21 △△ 4.38±0.24 *△△ | 0.235±0.017 0.354±0.017 0.262±0.015 △△ 0.245±0.014 △△ 0.241±0.016 △△ | 12.0±1.2 39.6±4.3 17.4±2.8 △△ 14.6±2.3 △△ 13.3±3.2 △△ | 281±29 192±14 247±27 △△ 261±34 △△ 269±23 △△ |
Annotate: compare △ P＜0.05 △ △ P＜0.01 with model group
Embodiment 8: injection Pericarpium Trichosanthis lyophilized powder is to the influence of mice anoxia enduring
Experiment medicine: injection Pericarpium Trichosanthis lyophilized powder of the present invention (section's medicament research and development company limited provides in the Guangdong).Add in the experiment water for injection by required dissolving prepare Pericarpium Trichosanthis injection.
Normal saline
Radix Salviae Miltiorrhizae Injection
Laboratory animal: 40 of Wistar II level rat, male and female half and half, body weight 200g-250g
Experimental technique: get 40 of Wistar mices, be divided into normal control group (physiologic dose brine), Pericarpium Trichosanthis injection high dose group (3g crude drug/kg), Pericarpium Trichosanthis injection small dose group (1g crude drug/kg), Radix Salviae Miltiorrhizae Injection group (0.2g crude drug/kg), 10 every group at random.Each medicine group is pressed the 0.2ml/10g body weight, respectively to each group medicinal liquid, and lumbar injection, behind the administration 30min, every mice difference lumbar injection isoproterenol 0.1ml/10g body weight then, is put into airtight container bottle with mice, the record mouse diing time.The results are shown in Table 3.
Table 3 injection Pericarpium Trichosanthis lyophilized powder to the influence of mice anoxia enduring (x ± s, min)
| Group | Number of animals (only) | Death time (min) |
| Normal control group Pericarpium Trichosanthis injection (greatly) Pericarpium Trichosanthis injection (little) Radix Salviae Miltiorrhizae Injection | 10 10 10 10 | 31.28±7.69 46.8±7.79 **△ 38.95±8.45 * 45.07±8.92 ** |
Annotate: with normal group contrast, * P＜0.05, * * P＜0.01.
Claims (15)
1, a kind of pharmaceutical composition of Pericarpium Trichosanthis is a freeze-dried powder injection, and by the extract 5-100% weight portion of Pericarpium Trichosanthis, pharmaceutically acceptable pharmaceutic adjuvant 0-95% weight portion is formed.
2, as claim 1 described pharmaceutical composition, it is characterized in that extract 5-20% weight portion by Pericarpium Trichosanthis, pharmaceutically acceptable pharmaceutic adjuvant 80-95% weight portion is formed.
3, as claim 1 or 2 described pharmaceutical compositions, it is characterized in that the content of total amino acids is counted more than 25% with arginine in the Pericarpium Trichosanthis extract.
4,, it is characterized in that every loading amount Pericarpium Trichosanthis extract is no less than 35mg as claim 3 described pharmaceutical compositions.
5,, it is characterized in that the content of total amino acids is counted more than 80% with arginine in the Pericarpium Trichosanthis extract as the pharmaceutical composition of claim 3 described Pericarpium Trichosanthiss.
6, as claim 3 described pharmaceutical compositions, it is characterized in that Pericarpium Trichosanthis extract prepares by the following method: get the recipe quantity Pericarpium Trichosanthis and decoct with water three times, 2 hours for the first time, second, three times each 1 hour, gradation filtered, and merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), adding ethanol makes and contains the alcohol amount and reach 70%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol, by 732 type cation exchange resiies, with an amount of washing resin of water for injection, reuse 1mol/L ammonia solution eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract; Acceptable accessories comprises the skeleton proppant that lyophilizing is used, and can be in mannitol, lactose, mannose, sorbitol, the low molecular dextran one or more.
7,, it is characterized in that the skeleton proppant uses mannitol, and the concentration of mannitol is 4-12% before the lyophilizing as claim 6 described pharmaceutical compositions.
8,, it is characterized in that the concentration before the mannitol lyophilizing is 8% as claim 7 described pharmaceutical compositions.
9,, it is characterized in that acceptable accessories also comprises solubilizing agent and the antioxidant of pharmaceutically accepting as claim 6 described pharmaceutical compositions.
10, a kind of preparation method of injection Pericarpium Trichosanthis lyophilized powder is characterized in that may further comprise the steps:
1) gets the recipe quantity Pericarpium Trichosanthis and decoct with water three times, merge three extracting solution and be evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), add high concentration ethanol and make and contain the alcohol amount and reach 60-80%, left standstill 24 hours, and got supernatant, filter, reclaim ethanol to there not being the alcohol flavor, by cation exchange resin, with an amount of washing resin of water for injection, reuse ammonia eluting, collect eluent, decompression removes the deammoniation flavor, and is concentrated into thick paste final vacuum drying, gets Pericarpium Trichosanthis extract;
2) Pericarpium Trichosanthis extract fully is dissolved in the water for injection, regulates pH value to 3-4 with hydrochloric acid, cold preservation 24 hours filters, and filtrate adds injection supplementary material, regulates pH value to 6.0-7.5 with sodium hydroxide test solution, fine straining, and packing, lyophilizing are promptly.
11, as the preparation method of claim 10 described injection Pericarpium Trichosanthis lyophilized powders, it is characterized in that may further comprise the steps:
1) getting the recipe quantity Pericarpium Trichosanthis decocts with water three times, 2 hours for the first time, second and third time each 1 hour, gradation filters, merging filtrate also is evaporated to the clear paste that relative density is 1.10-1.25 (30 ℃), adds 90% ethanol and makes and contain alcohol amount and reach 70%, leaves standstill 24 hours, get supernatant, filter, reclaim ethanol, by 732 type cation exchange resiies, with an amount of washing resin of water for injection, reuse 1mol/L ammonia solution eluting is collected eluent, and decompression removes the deammoniation flavor, and be concentrated into thick paste final vacuum drying, get Pericarpium Trichosanthis extract.
2) Pericarpium Trichosanthis extract of getting step 1) fully is dissolved in the water for injection, regulates pH value to 3-4 with hydrochloric acid, and cold preservation 24 hours filters, and filtrate is regulated pH value to 7.0 with sodium hydroxide test solution, fine straining after the active carbon decarburization, and packing, lyophilizing are promptly.
12, as the preparation method of claim 10 or 11 described injection Pericarpium Trichosanthis lyophilized powders, it is characterized in that also comprising the step of ultrafiltration, be meant step 2) back 5000 the ultrafilter membrane ultrafiltration excessively of cold preservation filtration in 24 hours, ultrafiltrate reuse sodium hydroxide test solution is regulated pH value to 6.0-7.5, fine straining, packing, lyophilizing gets final product.
13, as the application in the medicine aspect preparation treatment cardiovascular and cerebrovascular disease of the described Pericarpium Trichosanthis pharmaceutical composition of claim 1-9.
14, as claim 13 described Pericarpium Trichosanthis pharmaceutical compositions purposes in the medicine aspect preparation treatment cardiovascular and cerebrovascular disease, it is characterized in that Pericarpium Trichosanthis extract using dosage every day is 150mg to 400mg.
15, as the application of claim 14 described Pericarpium Trichosanthis pharmaceutical compositions in preparation treatment cardiovascular and cerebrovascular diseases medicament, it is characterized in that Pericarpium Trichosanthis extract using dosage every day is 200mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510121133 CN1823875A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition of trichosanthes rind and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510121133 CN1823875A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition of trichosanthes rind and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1823875A true CN1823875A (en) | 2006-08-30 |
Family
ID=36934815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510121133 Pending CN1823875A (en) | 2005-12-27 | 2005-12-27 | Medicinal composition of trichosanthes rind and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1823875A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102166038A (en) * | 2011-03-15 | 2011-08-31 | 深圳波顿香料有限公司 | Method for extracting snakegourd peel, application of snakegourd peel extract to cigarettes and cigarettes |
| CN102861121A (en) * | 2012-09-07 | 2013-01-09 | 西藏易明西雅生物医药科技有限公司 | Snakegourd peel injection formulation and preparation method thereof |
| CN103027911A (en) * | 2012-09-24 | 2013-04-10 | 西藏易明西雅生物医药科技有限公司 | Pharmaceutical composition, preparation and application thereof |
| CN108623698A (en) * | 2017-03-17 | 2018-10-09 | 上海医药集团股份有限公司 | PERICARPIUM TRICHOSANTHIS widow/polysaccharide GLP-1-1, preparation method and the usage |
-
2005
- 2005-12-27 CN CN 200510121133 patent/CN1823875A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102166038A (en) * | 2011-03-15 | 2011-08-31 | 深圳波顿香料有限公司 | Method for extracting snakegourd peel, application of snakegourd peel extract to cigarettes and cigarettes |
| CN102861121A (en) * | 2012-09-07 | 2013-01-09 | 西藏易明西雅生物医药科技有限公司 | Snakegourd peel injection formulation and preparation method thereof |
| CN102861121B (en) * | 2012-09-07 | 2014-06-18 | 西藏博睿生物科技有限公司 | Snakegourd peel injection formulation and preparation method thereof |
| CN103027911A (en) * | 2012-09-24 | 2013-04-10 | 西藏易明西雅生物医药科技有限公司 | Pharmaceutical composition, preparation and application thereof |
| CN103027911B (en) * | 2012-09-24 | 2014-07-23 | 西藏博睿生物科技有限公司 | Pharmaceutical composition, preparation and application thereof |
| CN108623698A (en) * | 2017-03-17 | 2018-10-09 | 上海医药集团股份有限公司 | PERICARPIUM TRICHOSANTHIS widow/polysaccharide GLP-1-1, preparation method and the usage |
| CN108623698B (en) * | 2017-03-17 | 2021-12-07 | 上海医药集团股份有限公司 | Trichosanthes peel oligo/polysaccharide GLP-1-1, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019076066A1 (en) | Bitter ganoderma lucidum spore powder and preparation method thereof | |
| CN104225217B (en) | A kind of Chinese medicine preparation for treating coronary heart disease and preparation method thereof | |
| CN1701787A (en) | Application of Danshensu in preparation of medicine for treating cerebrovascular diseases | |
| CN1726966A (en) | Preparation of oral disintegration tablet in use for treating disease of apoplexy and obstruction of qi in the chest | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1823875A (en) | Medicinal composition of trichosanthes rind and its preparation method | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN101143157A (en) | Tyrosol and tyrosol bypass salidroside plant extraction and preparation and use thereof | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN1762362A (en) | Medicinal composition with red sage root component for treating cardiovascular and cerebrovascular disease and its application | |
| CN111281958A (en) | A Chinese medicinal composition for treating apoplexy, apoplexy involving the channels and collaterals, coronary heart disease and angina pectoris due to blood stasis and obstruction of collaterals, and its preparation method | |
| CN105456307B (en) | Pinus massoniana twig bark extract for preventing and treating middle and late stage lung adenocarcinoma as well as preparation method and composition thereof | |
| CN1660378A (en) | Application of effective part of chrysanthemum flower | |
| CN1686275A (en) | Danhong freeze dried powder injection agent and its preparation method | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN1785350A (en) | Chinese medicinal preparation for freating coronary heart disease, brain arteriosclerosis and its preparation method | |
| CN102988478A (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
| CN1923803A (en) | Arginine rosmarinate, preparation method, pharmaceutical composition and use thereof | |
| CN100444851C (en) | Use of chrysanthemum total flavone for preparing drugs for treating arythmia | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method | |
| CN1943710A (en) | The application of radix ophioponis in the medicines for treating myocarditis and medicines containing its extracts with active elements | |
| CN1850185A (en) | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor | |
| CN1788753A (en) | General glycoside extract from tree peony root bark and its preparation method and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |